Seletracetam (Ucb 44212) lithium bromide is a SV2A modulator, intended for epilepsy research. It is an analog of Levetiracetam, an antiepileptic agent.

Seletracetam demonstrates a significantly higher affinity for the LEV-binding site, with a one-log-unit increase (pKi=7.1) compared to Levetiracetam (pKi=6.1). Additionally, in rat cortical neurons in vitro, Seletracetam lithium bromide effectively inhibits both high-voltage-activated calcium currents and the subsequent intracellular calcium increase. At concentrations ranging from 1 to 10 μM, Seletracetam lithium bromide also markedly reduces the amplitude and repetitive firing of population spikes in rat hippocampal slices, an effect induced by a high potassium/low calcium concentration fluid (HKLCF).

Seletracetam, administered via intraperitoneal injection as lithium bromide, has demonstrated significant efficacy in mitigating secondary generalized motor seizures in fully corneally-kindled mice, with an effective dose (ED50) of 0.31 mg/kg. In mice prone to audiogenic seizures, Seletracetam offers protection from clonic convulsions with an ED50 of 0.17 mg/kg. Further investigation reveals that doses ranging from 0.0074 mg/kg to 74 mg/kg enhance the generalized seizure threshold current, reduce the duration and severity of after-discharges, and display a considerably stronger effect than Levetiracetam. Studies conducted on female Wistar rats (200-220 g) that were amygdala-kindled showed that pre-seizure threshold determination administration of Seletracetam significantly elevates the generalized seizure threshold across all doses, demonstrating increases of 190% (0.0074 mg/kg), 302% (0.074 mg/kg), 429% (0.74 mg/kg), 433% (7.4 mg/kg), and 679% (74 mg/kg), indicative of its potent anticonvulsant properties.